Lucy Liu - Biomerica Director Operations
| BMRA Stock | USD 0.32 0.02 5.88% |
Insider
Lucy Liu is Director Operations of Biomerica
| Address | 17571 Von Karman Avenue, Irvine, CA, United States, 92614 |
| Phone | (949) 645-2111 |
| Web | https://www.biomerica.com |
Biomerica Management Efficiency
The company has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7648) %, meaning that it created substantial loss on money invested by shareholders. Biomerica's management efficiency ratios could be used to measure how well Biomerica manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.63. The current year's Return On Capital Employed is expected to grow to -0.86. At present, Biomerica's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 273.3 K, whereas Total Assets are forecasted to decline to about 7.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andre Marquette | Neuropace | N/A | |
| Paul Badawi | Sight Sciences | 49 | |
| Reay Brown | Sight Sciences | N/A | |
| Jesse Selnick | Sight Sciences | N/A | |
| Christopher Lesovitz | STRATA Skin Sciences | 41 | |
| Michael Favet | Neuropace | 54 | |
| Mark Saxton | Neuropace | 59 | |
| MBA BS | Sight Sciences | N/A | |
| Kevin Schmid | Modular Medical | 65 | |
| Marilyn Elson | Nexalin Technology | 71 | |
| John Liu | Sight Sciences | N/A | |
| David MD | Nexalin Technology | 62 | |
| HuiLan Wu | Ainos Inc | 63 | |
| Tyla Bucher | Movano Inc | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Martha Morrell | Neuropace | 67 | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| Nikolai Kabelev | STRATA Skin Sciences | 48 | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 |
Biomerica Leadership Team
Elected by the shareholders, the Biomerica's board of directors comprises two types of representatives: Biomerica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomerica. The board's role is to monitor Biomerica's management team and ensure that shareholders' interests are well served. Biomerica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomerica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allen Barbieri, Independent Director | ||
| Zackary Irani, Chairman, CEO and Pres | ||
| Hans Boehringer, VP RD | ||
| Gary CPA, Principal CFO | ||
| Steven Sloan, CFO Treasurer | ||
| Lucy Liu, Director Operations | ||
| Robert Carlson, Chief Officer |
Biomerica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomerica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 3.34 M | ||||
| Shares Outstanding | 16.82 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 13.01 % | ||||
| Number Of Shares Shorted | 562.41 K | ||||
| Price To Earning | (25.64) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.